Influenza Vaccine Quantification
Influenza Vaccine Quantification - Related Videos
02:58
Generating Recombinant Live-Attenuated Influenza Viruses for Vaccines
0 Views •
2025
The video showcases a method to create cold-adapted recombinant influenza viruses. It involves transfecting human cells with bi-directional plasmids, followed by incubation at lower temperature incubation to yield viruses suitable for vaccine production, characterized by reduced replication in warmer conditions.
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
0 Views •
Cited by 1 •
2015
There is an overall lack of knowledge about how vaccines work. Here we propose the combined use of reverse genetics and bone marrow chimeric mice to gain insight into the early host immune responses to vaccines with a special focus on dendritic cells and T cell immunity.
06:17
Expression and Purification of Virus-like Particles for Vaccination
0 Views •
Cited by 27 •
2016
Here, we present a protocol for synthesizing virus-like particles using either baculovirus or mammalian expression systems, and ultracentrifugation purification. This highly customizable approach is used to identify viral antigens as vaccine targets in a safe and flexible manner.
13:12
Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using Universal Antibodies in Simple Slot Blot Assays
0 Views •
Cited by 19 •
2011
A simple slot blot method was developed for the quantification of influenza viral hemagglutinin and neuraminidase using universal antibodies targeting their most conserved sequences identified through bioinformatics analyses. This innovative approach may provide a useful alternative to quantitative determination of all viral hemagglutinin and neuraminidase.
01:51
Vaccinations
0 Views •
2019
Overview Vaccination is the administration of antigenic material from pathogens to confer immunity against a specific microorganism. Vaccination primes the immune system to recognize and mount an immune response faster and more effectively if the real pathogen is encountered. Vaccinations are one of the most efficient ways to protect both individual humans and the general public from disease. A growing anti-vaccination skepticism risks the successes of vaccination programs that helped reduce...
FAQs
The assay translates antigen movement through an antibody-containing gel into a measurable precipitation zone. Hemagglutinin from disrupted virions or purified preparations reacts with the corresponding antibodies, producing a visible boundary. Comparing that zone with reference material allows the measured antigen amount to be expressed relative to a known standard rather than judged only by visual presence or absence.
Reference standards provide the benchmark needed to interpret precipitation-zone size quantitatively. Without that comparison, a zone would show that antigen-antibody interaction occurred but would not establish the amount present. Using standards therefore supports calculation of hemagglutinin concentration and helps determine whether a vaccine strain contains antigen at its intended dose.
The material analyzed may be disrupted virions or purified hemagglutinin, so the measured signal depends on which antigen preparation enters the gel. This distinction connects the assay result to the vaccine’s physical sample form while retaining the same antibody-based measurement principle. It enables antigen content to be assessed across relevant vaccine materials and production samples.
A typical workflow uses a vaccine sample containing disrupted virions or purified hemagglutinin, places it in an antibody-containing gel, and allows diffusion to produce a precipitation zone. The zone is then compared with reference standards, and the relationship is used to calculate antigen concentration. Results can be examined against the intended dose for the relevant strain.
Influenza vaccine quantification supports manufacturing quality control, batch release, and evaluation of seasonal formulations. It can also help researchers compare production processes by showing whether those processes yield the expected antigen content. These uses make the measurement relevant both to routine decisions about vaccine batches and to assessment of changing seasonal compositions.
Hemagglutinin measurement connects a vaccine’s physical composition with the antigen dose intended to support immune protection. Consistent quantification helps verify that each influenza strain is represented at the expected level, while comparisons among seasonal formulations or production processes provide context for interpreting how manufacturing choices may affect vaccine consistency and subsequent immunological evaluation.